drugset / Trial / NCT01074450
Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions
RandomizedCrossoverOpen-label
Summary
The object of this study was to compare the relative bioavailability (rate and extent of absorption) of Pramipexole Dihydrochloride Tablets 0.25 mg by Barr Laboratories, Inc. with that of Mirapex® Tablets 0.25 mg distributed by Boehringer Ingelheim Pharmaceuticals, Inc. following a single oral dose in healthy adults under fasting conditions.
Timeline
- Start
- 2005-02
- Primary completion
- 2005-03
- Completion
- 2005-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pramipexole | Unknown | 0.25 mg | Oral |
Indications
No indication recorded.